Form 4: MAIA Biotechnology Director Acquires Significant Stock Options

Ramiro Guerrero, a Director at MAIA Biotechnology, Inc., has acquired 20,380 stock options with an exercise price of $1.80, vesting immediately.

Summary

• Ramiro Guerrero, a Director of MAIA Biotechnology, Inc. (MAIA), acquired 20,380 stock options.
• The transaction date for the acquisition was June 30, 2025.
• The exercise price for these stock options is $1.80 per share.
• The options were granted pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan.
• These stock options vest 100% on the grant date, June 30, 2025, and are exercisable from that date.
• The expiration date for these stock options is June 30, 2035.
• Following this transaction, Ramiro Guerrero beneficially owns 20,380 derivative securities (stock options) and 20,380 underlying common stock shares.

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director is generally viewed positively as it aligns management's interests with shareholders and can signal confidence in the company's future performance. The immediate vesting further reinforces this alignment.

Positives

• A Director's acquisition of stock options can signal confidence in the company's future prospects and alignment of interests with shareholders.
• The immediate 100% vesting of the options provides the Director with immediate equity exposure and incentive.

Future Outlook

This Form 4 filing reports a past transaction and does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

Insider transactions, such as the acquisition of stock options by a director, are common in the biotechnology industry as a form of executive compensation and incentive. Such transactions are closely watched by investors for signals regarding management's confidence in the company's future.

Stakeholder Impact

• Shareholders: The acquisition of stock options by a director may be perceived as a positive signal, potentially increasing investor confidence and aligning management incentives with shareholder value creation.

Key Dates

Keywords

MAIA Biotechnology, MAIA, Ramiro Guerrero, Stock Options, Insider Transaction, SEC Form 4, Equity Incentive Plan, Director Compensation, Biotechnology